XML 38 R23.htm IDEA: XBRL DOCUMENT
v3.23.1

Commitments and Contingencies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
ANA Merger |
Schedule of milestone events | ​
| ​ | ​ | ​ | ​ | ​ |
Milestone Event | ​ | ​ | ​ | ​ | ​ | Milestone Payment
First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement) | ​ | ​ | $ | ​ | 45.0 million
Sales Milestones: | ​ | ​ | ​ | ​ | ​ | ​
Milestone Event – Worldwide Cumulative Net Sales of a Niclosamide Product | ​ | ​ | ​ | ​ | ​
equal to or greater than: | ​ | ​ | ​ | ​ | ​ | Milestone Payment
$500 million | ​ | ​ | ​ | $ | 9.0 million
$1 billion | ​ | $ | 13.5 million
$3 billion | ​ | $ | 36.0 million
$5 billion | ​ | $ | 72.0 million
​

X
- Definition Tabular disclosure of future milestone payments to be paid up on achieving of milestone events. + References No definition available. + Details
Name: | nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock
Namespace Prefix: | nrbo_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |